Effective vaccine development for human immunodeficiency virus type 1 (HIV-1) will require assays that ascertain the capacity of vaccine immunogens to elicit neutralizing antibodies (NAb) to diverse HIV-1 strains. To facilitate NAb assessment in peripheral blood mononuclear cell (PBMC)-based assays, we developed an assay-adaptable platform based on a Renilla luciferase (LucR) expressing HIV-1 proviral backbone. LucR was inserted into pNL4-3 DNA, preserving all viral open reading frames. The proviral genome was engineered to facilitate expression of diverse HIV-1 env sequences, allowing analysis in an isogenic background. The resulting Env-IMC-LucR viruses are infectious, and LucR is stably expressed over multiple replications in PBMC. HIV-1 neutralization, targeting TZM-bl cells, was highly correlative comparing virus (LucR) and cell (firefly luciferase) readouts. In PBMC, NAb activity can be analyzed either within a single or multiple cycles of replication. These results represent advancement toward a standardizable PBMC-based neutralization assay for assessing HIV-1 vaccine immunogen efficacy.
Introduction
An efficacious vaccine against HIV-1 may require the elicitation of a potent, broadly neutralizing antibody (NAb) response (Baba et al., 2000; Haynes and Montefiori, 2006; Johnston and Fauci, 2007; Mascola et al., 2000; McMichael, 2006; Nishimura et al., 2003; Pantophlet and Burton, 2006; Phogat et al., 2007; Plotkin, 2008; Shibata et al., 1999) . The ability to develop immunogens capable of eliciting such antibodies is integrally linked to a requirement for standardized, high-throughput in vitro assay measurements that reflect the in vivo potency and breadth of NAb responses elicited by natural infection or experimental vaccine immunogens (Fenyo et al., 2009; Mascola et al., 2005b; Montefiori et al., 2007; Polonis et al., 2008) . It is not currently known which in vitro assay results may correlate with antibody protection from HIV-1 infection in vivo, and several assay formats will continue to have to be employed to assess antibody responses elicited by vaccine immunogens (Fenyo et al., 2009; Pantophlet and Burton, 2006; Polonis et al., 2008 Polonis et al., , 2009 . With support from multi-institutional HIV/AIDS vaccine initiatives [NeutNet (Neutralization Network) Project, CAVD/CA-VIMC, Global HIV/AIDS Vaccine Enterprise (GHAVE), NIH Center for HIV/AIDS Vaccine Immunology (CHAVI), and International AIDS Vaccine initiative (IAVI)], great efforts are being invested in the discovery, standardization and implementation of new assay platforms for assessing breadth and potency of neutralizing antibodies (Fenyo et al., 2009; Mascola et al., 2005a; Montefiori et al., 2007; Montefiori, 2009; Polonis et al., 2008) . A comprehensive review of the strengths and differences between the two most widely utilized neutralization assays, the PBMC-and the
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Virology j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y v i r o pseudovirion-based neutralization assays, was recently published by Polonis et al. (Polonis et al., 2008) . Improvements in PBMC assay performance are urgently needed. While considered to be more physiologically relevant, the PBMC assay is labor-intensive, expensive and not practical for high-throughput analysis (D'Souza et al., 1997; Gauduin et al., 1996) . This assay also exhibits substantial variability owing in part to donor PBMC variability , and to the extensive use of primary virus isolates which complicates standardization. Moreover, the assay has been dependent on measurements of HIV-1 p24 antigen production as the endpoint, requiring extensive washout of HIV-1-positive sera to avoid artifacts but also reducing the sensitivity of the assay. While HIV-1 antibody neutralization in a single infectious cycle can be measured in PBMC by using flow-cytometry, this approach still involves several complex handling steps (Darden et al., 2000; Mascola et al., 2002) . Thus, current PBMC-based assays are not easily amendable to highthroughput and standardized analysis.
However, significant improvements in assay standardization and performance have been made by creating genetically engineered cell lines as host-cell targets that stably express defined levels of CD4, CCR5 and CXCR4 (Jones et al., 2007; Montefiori, 2005; Ochsenbauer-Jambor et al., 2006; Platt et al., 1998; Richman et al., 2003; Wei et al., 2002) . In certain cell lines, reporter genes have been introduced that are responsive to HIV-1 infection. For example, the TZM-bl cell line (Wei et al., 2002) expresses firefly luciferase in response to Tat expression following HIV-1 infection with either replication competent or Envpseudotyped viruses. TZM-bl cells enable sensitive, quantitative and high-throughput measurements of HIV-1 infection and inhibition with a linear dynamic range of several orders of magnitude (Montefiori, 2009; Wei et al., 2002) , properties which contribute to their wide use as an easily transferable and reproducible method for assessing neutralizing antibody activity (Montefiori, 2009 ). Furthermore, it is necessary to screen vaccine sera against panels of genetically diverse viruses (Li et al., 2005; Li et al., 2006) to evaluate the breadth of antibody responses elicited by vaccine immunogens, and for this reason, pseudovirions have certain advantages. HIV-1 env genes can be easily cloned from plasma viral RNA or infected cells, and coexpressed by transfection with an env-minus viral backbone generating infectious, replication-defective, Env-pseudotyped virus-like particles (pseudovirions) . In addition to the TZM-bl assay, another neutralization assay utilizing pseudovirions is based on a viral backbone that, in place of env, encodes the firefly luciferase gene which is expressed subsequent to infection of target cells. This assay is robust in cell lines (e.g. U87) that express CD4, CCR5 and CXCR4 (Binley et al., 2008; Petropoulos et al., 2000; Richman et al., 2003) . However, when PBMC or other primary cells are used as targets of infection this pseudovirus approach is not sufficiently robust due to a weak luciferase signal-tonoise ratio, a limitation resulting in part from single-round infection (Montefiori, unpublished) . Furthermore, while these assays offer certain advantages, pseudovirions which are produced in cell lines like 293T do not always resemble virus produced in primary cells (reviewed in ). Incorporation of unprocessed gp160 (Herrera et al., 2005) , producer-cell dependent post-translational modification of Env with glycan (Willey et al., 1996) and incorporation of host-cell proteins into progeny virions (Bastiani et al., 1997; Fortin et al., 1997; Hioe et al., 2001; Rizzuto and Sodroski, 1997) may influence infectivity and neutralization sensitivity (Bastiani et al., 1997; Sawyer et al., 1994; Willey et al., 1996; Zhang et al., 1997) .
In this study, we describe an approach that combines the advantages of PBMC-based assays with those of replication competent molecular clones of reporter viruses. We introduce a recombinant HIV-1 proviral backbone that preserves all viral open reading frames (orfs), is replication competent, stably expresses Renilla reniformis luciferase (LucR) and allows different env sequences to be shuttled in and expressed in cis. This approach facilitates the construction of reference panels encoding env sequences from genetically diverse strains of HIV-1, including recently described transmitted/founder viruses Salazar-Gonzalez et al., 2008 , 2009 . The response of the LucR readout to NAb is nearly identical to that of firefly luciferase when measured in the TZM-bl assay. Using PBMC as host-cell targets, the Env-IMC-LucR viruses enable sensitive, quantifiable assessment of infection and NAb activity, which can be measured either within a single cycle or after multiple rounds of virus replication. The robust and simplified assay read out enables analysis of large sample numbers and, thus, the approach represents a significant advancement towards the establishment of standardized high-throughput PBMC-based neutralization assays.
Results

Generation of a replication competent Renilla luciferase-expressing HIV-1 proviral DNA backbone
Since our objective was to create a versatile approach for sensitive and quantitative analysis of HIV-1 infection and the inhibition thereof in primary cells, we constructed a reporter HIV-1 proviral DNA backbone, pNL-LucR.T2A, which is replication competent, encodes all viral open reading frames and stably expresses a luciferase reporter gene over multiple rounds of virus replication. The sea pansy Renilla reniformis luciferase (LucR) gene was selected as a reporter since it comprises fewer nucleotides (935 vs. 1652 with firefly luciferase), a feature that we hypothesized would favor its retention within the genome during virus replication. LucR was inserted into the genome at the position of nef and linked in-frame at the 5′ end of nef with a "self-cleaving" T2A sequence (54 nucleotides) ( Fig. 1) (Szymczak et al., 2004) . During translation, the T2A sequence causes a ribosomal skip that impairs normal amino acid peptide bond formation between the penultimate glycine and the C-terminal proline ( Fig. 1) (Donnelly et al., 2001a,b) . The ribosomal skip releases the newly synthesized polypeptide as translation of the downstream sequence continues.
The principal purpose for constructing the pNL-LucR.T2A reporter proviral DNA backbone was to facilitate the analysis of HIV-1 inhibitory molecules, particularly neutralizing antibodies, against panels of env containing reference viruses in primary cells. Therefore, a molecular strategy was devised to best accommodate the expression of genetically diverse Envs within the pNL-LucR.T2A Fig. 1 . Schematic representation of the insertion of the Renilla luciferase gene into the NL4-3 viral backbone and the "shuttling in" of heterologous env ectodomain sequences. The LucR gene and a T2A peptide (amino acid sequence underlined) were fused in-frame and inserted between the NL4-3 env and nef genes. * indicates the co-translational cleavage point between the penultimate and last amino acid of T2A and the arrow indicates the start codon of Nef. The nt sequence is depicted for the junction between the env TAA and LucR gene ATG. Furthermore, the "shuttling in" of heterologous env ectodomain sequences between the viral KpnI site (NL4-3 nt 6343) and the introduced silent BstBI site (NL4-3 nt 8301) in the membrane-spanning domain is depicted.
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backbone, generating the NL-LucR.T2A-Env.ecto constructs. All LucR.T2A-containing proviruses described here are collectively referred to as Env-IMC-LucR viruses (IMCinfectious molecular clone) ( Fig. 1 and Supplemental Fig. 1 ). The nucleotide sequence of HIV-1 env comprises the Rev responsive element (RRE) as a product of transcription, encodes the gp41 Env that interacts with p17 Gag (MA) via its cytoplasmic domain, and overlaps with the accessory genes vpu, tat and rev. We elected to insert only the fragment of the heterologous env that encodes the respective Env ectodomain (Fig. 1) , maintaining the NL4-3 cytoplasmic tail. This strategy retains expression of all viral open reading frames (orfs), avoids genetic chimerisms in tat and rev, and heterologous viral protein-protein interaction between the gp41 tail and MA (Freed and Martin, 1995) . Further rationale for this strategy includes findings that show (i) genetic recombination within the env membrane-spanning domain (MSD) is one of few functionally favored env recombinant points naturally occurring in vivo (Simon-Loriere et al., 2009 ) and (ii) neutralization profiles of viruses bearing interclade recombinant envs are predictable based on the clade/strain of the Env ectodomain (Binley et al., 2004) . Three Env-IMC-LucR viruses (NL-LucR.T2A, NL-LucR.T2A-BaL.ecto and NL-LucR.T2A-SF162.ecto) were analyzed by western blot in comparison to the cognate viruses lacking the LucR.T2A insert (NL4-3, NL-BaL.ecto, NL-SF162.ecto). Additional controls including NL-LucR-T2A.FS and NLENG1-IRES were analyzed in parallel. NL-LucR-T2A.FS has a frameshift (FS) mutation in the T2A sequence, impairing synthesis of Nef. NLENG1-IRES (Kutsch et al., 2002; Levy et al., 2004) was included as a Nef over-expressing positive control. Viral protein expression was analyzed following the transfection of proviral DNA into 293T cells. Each of the Env-IMC-LucR constructs expressed Nef at a similar or slightly reduced level compared to the non-LucR.T2A parental viruses ( Fig. 2A ). As expected, Nef expression was not detected from the NL-LucR-T2A.FS virus. A replica blot probed with anti-Renilla luciferase antibody indicated expression of LucR from the LucR.T2A-containing viruses ( Fig. 2B ). Neither the anti-Nef nor the anti-LucR antibody detected a band consistent with the molecular mass calculated for that of a LucR-Nef fusion protein (data not shown), indicating the T2A peptide functions efficiently to generate separated LucR and Nef proteins. Probing with anti-Gag MAb demonstrated the proteolytic processing of Gag was normal ( Fig. 2C ) and that a similar amount of each of the viruses was produced and analyzed, results that were confirmed by p24 ELISA (data not shown).
The infectivity of the reporter viruses was compared to that of the cognate non-reporter viruses using the TZM-bl assay. In at least three independent experiments, the titers of transfection-derived stocks were found to be similar and ranged from 5 × 10 6 to 1 × 10 7 TZM-bl IU per ml (data not shown). Infectivity per ng p24 was also comparable for all of the virus stocks analyzed (data not shown). The linear range of the LucR readout was examined by infecting TZM-bl cells in triplicate at multiplicities of infection (MOI) equivalent to 10, 1, 0.1 and 0.01 (based on ß-galactosidase enumeration). After 48 h, the cells were analyzed for both firefly luciferase (expressed by the TZM-bl cell line) and LucR expression (from the integrated reporter provirus). A linear response of both LucR and firefly luciferase activity was detected for each virus at MOIs equal to 0.01, 0.1 and 1 (Fig. 3) . Moreover, infection with each of the Env-IMC-LucR viruses resulted in nearly identical firefly luciferase values as their respective parental non-reporter viruses, indicating similar infectivity in the TZM-bl cell line. We further examined the effect of MOI on the linearity of the LucR readout by calculating the ratio of virus-encoded LucR to TZM-bl cell-encoded firefly luciferase at each virus inoculum ( Table 1) . The ratios were similar at MOIs of 0.01, 0.1 and 1, consistent with the linearity of LucR and firefly luciferase activity depicted in Fig. 3 . However, the ratio markedly increased at a MOI of 10, indicating greater expression of LucR relative to that of firefly.
Additional genes inserted into the viral genome can have deleterious effects on viral replication, i.e. severely delayed replication kinetics, and deletions can be rapidly selected. To determine whether the Env-IMC-LucR reporter viruses were replication competent, 2 × 10 6 PHA-P stimulated PBMC were infected at a low MOI of 0.0025 (equivalent to 5×10 3 TZM-bl IU) with NL-LucR.T2A, NL-LucR.T2A-BaL.ecto, NL-LucR. T2A-SF162.ecto, and the respective non-LucR.T2A parental viruses. Representative results from independent experiments, measuring p24 antigen production as an endpoint, demonstrate that the Env-IMC-LucR viruses are replication competent and have only slightly delayed replication kinetics compared to their respective non-reporter parental viruses ( Fig. 4 ). Similar results were obtained when PBMC from additional donors were used (data not shown). Smaller differences in replication kinetics were observed when PBMC were infected at a higher MOI (data not shown).
Next, we examined whether the LucR gene was stably maintained in, and expressed from, the viral genome over multiple cycles of virus replication. For this, PHA-P stimulated PBMC were infected with transfection-derived NL-LucR.T2A-BaL.ecto and NL-LucR.T2A-SF162. ecto viruses (5 × 10 3 IU = MOI of 0.0025). Culture supernatants containing virus were collected after 6, 9 and 14 days and cryopreserved. TZM-bl cells were then infected in triplicate with 3 five-fold dilutions of the 293T transfection-and PBMC infection-derived virus supernatants. Overall infectivity was measured by cell-encoded firefly luciferase activity while LucR activity was determined to assess the relative viral reporter gene expression. Values from those input dilutions yielding relative light unit (RLU) values within the linear range (as determined in Fig. 3 ) were then used to calculate the ratios of LucR to firefly luciferase. As shown in Fig. 5 , the ratios remained essentially constant, indicating that per infectious unit of virus produced in PBMC over time, expression of virally-encoded LucR did not change significantly. These results were reproduced in three separate experiments and the findings indicate that LucR is stable within the reporter virus backbone over multiple rounds of replication. In an additional experiment (data not shown), infected PBMC cultures were either carried over 28 days by feeding with freshly stimulated cells every five days or 500 μl volumes of PBMC supernatants were passaged cell-free onto fresh PBMC every seven Table 1 Ratio of Renilla to firefly luciferase.
Virus
Multiplicity of infection 10.0 1.0 0.1 0.01 NL-LucR.T2A 2.5 a 1.4 1.3 1.3 NL-LucR.T2A-BaL.ecto 8.2 1.1 1.0 0.9 NL-LucR.T2A-SF162.ecto 6.4 0.9 0.9 0.9 a The ratio was determined in TZM-bl cells 2 days after infection with the indicated viruses. ecto. PHA-P stimulated PBMC were infected overnight (MOI of 0.0025), washed twice and cultured for 14 days in 5 mL of medium. 2 mL supernatants were collected at the indicated time points to measure p24 antigen and the medium removed from the samples was replenished. (A) On day 6, the cell cultures were split 1:2 and fed with fresh medium and uninfected cells from the same donor. (B) On day 6, the cell cultures were split 1:2 and fed with fresh medium only. Data in A and B represent results from two independent experiments with PBMC from different donors. days. Virus supernatants harvested on the days of feeding were analyzed as described for Fig. 5 . Under these conditions, a reduction in LucR expression was observed, indicating that LucR expression will decrease after an extended time in culture (data not shown).
Analysis of HIV-1 neutralizing antibodies in TZM-bl and NOMI cells
The infection of TZM-bl cells, as quantified by LucR expression, closely correlated with quantification via firefly luciferase. This supported the notion that the NL-LucR.T2A reporter virus backbone, and the LucR readout, would enable sensitive measurement of neutralizing antibody activity against HIV-1. Therefore, a systematic analysis was undertaken by analyzing neutralization in two different cell lines, as well as PBMC, with Env-IMC-LucR reporter viruses expressing HIV-1 envs from different virus strains, including transmitted/founder viruses. First, the NL-LucR.T2A-BaL.ecto and NL-LucR. T2A-SF162.ecto reporter viruses were analyzed in the cell lines, TZM-bl and NOMI. The viruses were incubated for 1 h with dilutions of each of three broadly neutralizing antibodies (NAbs) (IgG1b12, 2G12 and 4E10) or the T20 fusion inhibitor. Thereafter, the virus/inhibitor mixture was added to either the TZM-bl or NOMI cells and inhibition was assessed two days later by measuring virus-encoded LucR activity in the cell lysates ( Fig. 6 ). The TZM-bl cell lysates were also assessed for cellencoded firefly luciferase activity. As expected, in TZM-bl cells the firefly luciferase readout showed there was a dosage dependent effect for each inhibitor on virus infectivity. For both viruses tested, the "% neutralization" curves for the LucR readout were nearly identical to those of the firefly readout (representative results shown in Figs. 6A and B) . IC50 values were calculated from multiple independent experiments (n =3 to 4) using both the LucR and the firefly luciferase readout. As shown in Figs. 6C and D, the LucR measurements (illustrated with solid symbols) were highly reproducible, and similar to those generated when measuring TZM-bl firefly luciferase (shown with open symbols). When neutralization was analyzed using NOMI cells (reporter T-cells grown in suspension) as targets of infection, very similar dose-response curves were generated in independent experiments (data not shown). Additionally, the level of inter-assay variation was relatively small. In 5 to 6 independent experiments with NL-LucR.T2A-BaL.ecto, the mean IC 50 values for T20, IgG1b12, 2G12 and 4E10 were 0.15 ± 0.03, 0.47 ± 0.25, 1.17 ± 1.2 and 8.74 ± 4.71, respectively ( Fig. 6E ). Utilizing NL-LucR.T2A-SF162.ecto, the mean IC 50 values in 5 independent experiments for T20, IgG1b12, 2G12 and 4E10 were 0.78± 0.09, 0.24 ± 0.14, 2.56± 1.59 and 13.33± 6.26, respectively (Fig. 6F ).
Analysis of HIV-1 antibody inhibition in primary PBMC with the NL-LucR. T2A-Env.ecto reporter backbone While recombinant reporter cell line based assays are widely used to analyze NAb activity, these assays do not always give the same results as those generated using PBMC (Binley et al., 2004; Brown et al., 2007; Moody et al., 2010) , highlighting the importance of using primary cells, including PBMC, to screen NAbs and/or patient plasma for anti-viral activity. To examine the utility of the Env-IMC-LucR reporter viruses in a PBMC-based assay, we analyzed neutralization of the NL-LucR.T2A-BaL. ecto and NL-LucR.T2A-SF162.ecto viruses by measuring Renilla luciferase two days after infection. Normal human PHA-P stimulated PBMC were infected in 96-well plates at an MOI of 0.625 in the presence of IgG1b12, 2G12, 4E10 or T20. Two days post infection, there was a clear doseresponse inhibitory effect for each inhibitor tested (Figs. 7A and B), demonstrating utility of the Env-IMC-LucR reporter backbones for analyzing NAb activity.
The two-day assay is of sufficient duration that the virus likely replicates beyond a single cycle of infection, resulting in RLU values up to four logs above the negative control for the viruses and MOI tested here. Next, we determined whether the assay sensitivity was sufficient to quantify a single cycle of virus infection and, ultimately, NAb inhibition thereof. PBMC were infected with NL-LucR.T2A-SF162.ecto (MOI= 0.2) in medium supplemented with or without 2 μM of the protease 8A and B) .
To further validate the assay platform, we expanded the analysis to include a broader panel of envs expressed in the pNL-LucR.T2A reporter backbone, including the transmitted/founder (T/F) clade B viral envs WITO4160, WEAU0575, CH040, CH058 and CH077 . The infectivity and replication competence of each recombinant virus was demonstrated in the TZM-bl assay and in PBMC, respectively, to be similar to the cognate parental virus (data not shown). Furthermore, experiments to be reported elsewhere demonstrated that the cellular tropism of these recombinant viruses was identical to that observed for the parental full-length T/F viruses (Ochsenbauer et al., unpublished) . Using PBMC from a single donor, inhibition of five T/F env-reporter viruses and two control envreporter viruses (NL-LucR.T2A-BaL.ecto and NL-LucR.T2A-SF162. ecto) was analyzed against NAbs, sCD4, HIVIG and clade-specific pooled plasma. The inhibitory activity of each inhibitor is illustrated as IC 50 and IC 80 values ( Table 2 ). The results indicate that (i) the assay (in PBMC) measured an IC 50 and in most cases an IC 80 for BaL and SF162 exceptions, the T/F viruses exhibited similar sensitivity to MAbs as the Tier 1 controls, (iii) T/F viruses were generally most sensitive to the 2G12, 2F5, and 4E10 MAbs, (iv) T/F viruses were generally less sensitive to sCD4 compared to control viruses, and (v) with few exceptions, T/F viruses are similarly resistant (b20) to plasmas 1648 and 1652 and more resistant to plasmas 1686 and BB81 compared with NL-LucR.T2A-BaL.ecto and NL-LucR.T2A-SF162.ecto.
Differences in the susceptibility of different donor PBMC to virus infection have been reported (Spira and Ho, 1995) , and anecdotal evidence also suggests donor dependent variation of neutralization sensitivity. Facilitated by the high-throughput capability of this approach, the observation of variation in neutralization activity among different donor PBMC was analyzed. In 75 different donor PBMC, we quantified susceptibility to infection by NL-LucR.T2A-BaL. ecto, and virus inhibition by IgG1b12, 4E10 and HIVIG ( Fig. 9) . For the 75 different donors analyzed, the mean LucR value in the absence of inhibitor was relatively uniform, with a mean of 36,530 ± 18,525 LucR RLU (Fig. 9D ) and a range of approximately 20-fold. Using IC 50 as a cutoff, IgG1b12, 4E10 and HIVIG were inhibitory in 100%, 76% and 100% of the donor PBMC, with mean IC 50 values of 3.9± 4.2 μg/mL, 9.5 ±6.5 μg/mL and 300.9± 369.4 μg/mL, respectively (Figs. 9A-C). Using IC 80 as the cutoff, IgG1b12, 4E10 and HIVIG were inhibitory in 94%, 40% and 99% of the donor PBMC, with mean IC 80 values of 8.2± 5.8 μg/mL, 13.5± 7.3 μg/mL, and 757.3± 603.7 μg/mL, respectively. Notably, significant variation in sensitivity to the MAbs was observed among the different donor PBMC. IgG1b12 IC 50 values ranged from 0.06 to 24.01 μg/mL (400-fold), 4E10 from 0.08 to N25 μg/mL (N300-fold) and HIVIG from 0.5 to 2050 μg/mL (4100-fold). Similar results were obtained in repeat neutralization assays with PBMC from a subset of 12 donors, indicating that the high variability was a real biologic effect and not simply assay-to-assay variability. Interestingly, for a given donor PBMC a consistent pattern of variation was not observed among the three inhibitors tested. For example, potent inhibition by IgG1b12 for a given donor PBMC did not necessarily correlate with strong virus inhibition by the other antibodies in the same donor PBMC. A possible explanation for the observed variation could be the differences in the susceptibility of different donor PBMC to virus infection. However, although differences in virus susceptibility were observed, the range was much smaller (approximately 20-fold) than for variation of neutralization, and there was not an apparent correlation with neutralization sensitivity.
To further address this point, we analyzed inter-assay variation using two different donor PBMC in three independent experiments each. The two donors PBMC were infected with NL-LucR.T2A-BaL. ecto in the presence of 4E10, 2F5, IgG1b12, 2G12 and sCD4, respectively (Fig. 10 ). The range in IC50 values for each inhibitor was relatively small for each PBMC donor. For Donor 1, 4E10 IC 50 values ranged from 0.02 to 0.09 μg/mL, 2F5 from 0.53 to 1.25 μg/mL, IgG1b12 from 0.2 to 0.36 μg/mL, 2G12 from 0.008 to 0.32 μg/mL and sCD4 from 1.01 to 2.03 μg/mL. For Donor 2, 4E10 IC 50 values ranged from 0.22 to 0.39 μg/mL, 2F5 from 0.50 to 0.56 μg/mL, IgG1b12 from 0.09 to 0.35 μg/mL, 2G12 from 0.03 to 0.56 μg/mL and sCD4 from 0.59 to 0.61 μg/mL. This result would argue that the magnitude of variation in IC50 values observed among the 75 PBMC donors was not due to inherent variability in the NL-LucR assay platform itself, but was in fact a characteristic of the primary cells. A comprehensive study of this phenomenon will be reported elsewhere by Wieczorek et al.
Discussion
The assessment of immunization strategies for eliciting potent and broadly neutralizing antibodies requires standardized, high-throughput, transferable in vitro assays informative of NAb potency and breadth in vivo. Significant progress in assay standardization has been made through technologic advances in genetically engineered cell lines and pseudovirion-based assays (2005; Li et al., 2005 Li et al., , 2006 Mascola et al., 2005a; Montefiori, 2009; Richman et al., 2003) . In 2005, the Laboratory Standardization Subcommittee for the Global HIV/AIDS Vaccine Enterprise (GHAVE) recommended these methods as a standardized approach to assess sera NAbs from vaccine trials (2005; Mascola et al., 2005a; Montefiori, 2009 ). However, qualitative and quantitative differences in NAb-virus inhibition have been identified between this assay platform and primary cell-based NAb assays (reviewed in ). For example, MAb to phosphatidylinositol phosphate is inhibitory to HIV-1 infection when analyzed in the PBMC assay but not in the TZM-bl assay (Brown et al., 2007) . In a collaborative study with Moody and colleagues, we recently validated these findings and elucidated a mechanism for these differences utilizing the Env-IMC-LucR viruses described here (Moody et al., 2010) . Discrepancies have also been reported for the MAbs 4E10 and X5 when analyzed in PBMC assays compared with pseudovirion assays. For example, 4E10 neutralized all tested viruses in the pseudovirion assay but not in the PBMC assay (Binley et al., 2004) whereas the X5 MAb neutralized virus in the PBMC assay but not in the pseudovirus assay. These findings highlight the importance of using primary cells, including PBMC, to screen NAbs and/or patient plasma for anti-viral activity. Moreover, since correlates between in vitro assay measurements of neutralizing activity and in vivo protection are not known, assessment of NAbs using different assay approaches is currently recommended (Fenyo et al., 2009; Pantophlet and Burton, 2006; Polonis et al., 2008 Polonis et al., , 2009 ). Thus, the concept behind this report, and the Env-IMC-LucR viruses, was development of a virologic approach to overcome problems of the PBMC-based assay that to date have limited its utility in the global vaccine discovery effort. Key features of the Env-IMC-LucR-based assay that underpin a significant advancement in PBMC assay performance and eventual integration into the armamentarium for vaccine trials immune monitoring include, (i) expression of env from within the viral genome (in cis), (ii) replication of the recombinant virus beyond a single cycle of infection, (iii) a highly specific, sensitive and quantifiable endpoint (LucR) amenable to high-throughput testing and standardization, (iv) stable expression of LucR in the viral genome over multiple cycles of replication, (v) a molecular strategy for expressing functional envs (including those from other viral clades) in the pNL-LucR.T2A backbone with minimal disruption to other viral genes, and cis-and trans-acting functions, and (vi) the versatility to assess NAbs in various (primary) host-cell targets and assay formats.
In response to discordant results observed between recombinant/ pseudovirion-and PBMC-based assay platforms, the Comprehensive Antibody Vaccine Immuno-Monitoring Consortium (CA-VIMC) has been exploiting Env-IMC-LucR viruses to establish a standardized PBMC assay for assessing vaccine sera. One of the principal challenges is interlaboratory and inter-assay variation. At least in part, this may be due to the differential susceptibility of different donor PBMC to HIV-1 infection (Spira and Ho, 1995) as well as detection of neutralization . Taking advantage of the high-throughput capability and accuracy of the Env-IMC-LucR-based assay, we examined variation in measurement of NAb potency among 75 different donor PBMC. Using a single stock of virus (NL-LucR.T2A-BaL.ecto) to infect the PBMC in the presence of HIVIG and the MAbs IgG1b12 and 4E10, we demonstrated a level of donor-to-donor variability that exceeded 2 orders of magnitude in IC 50 values (Fig. 9) . Similar variation among the same 75 donor PBMC was observed with the anti-phospholipid MAb PGN632, reported elsewhere (Moody et al., 2010) . The 75 donor PBMC were also analyzed for susceptibility to NL-LucR.T2A-BaL.ecto infection, and while differences were detected, no correlation was observed with potency of NAb inhibition (Fig. 9D) . Importantly, our data indicate that inter-assay variation does not per se result from the reporter virus-based assay platform, but that high variability was a real biologic effect attributable to use of different donor PBMC. When independent experiments were repeated multiple times on PBMC from two individual donors, respectively (Fig. 10) , the ranges in IC 50 values for each inhibitor were low for each respective donor PBMC. Moreover, using a similar assay configuration to assess neutralization in the NOMI T-lymphocyte cell line (Jones et al., 2007) , minimal inter-assay variation was observed: IgG1b12 and 4E10 demonstrated a 4.98-fold and 4.16-fold variation in IC 50 values, respectively (Figs. 6E and F) . Thus, our findings demonstrate substantial differences in the extent of antibody neutralization measured among different donor PBMC. Studies to elucidate factors that account for differences in NAb potency detected among different donor PBMC, and to overcome the resulting assay limitations, are ongoing within the CA-VIMC and will be reported elsewhere (Wieczorek et al., unpublished) . It has been recommended that the magnitude and breadth of NAb responses elicited by vaccine immunogens be assessed against panels of genetically diverse viruses (Mascola et al., 2005a) . For the pseudovirion assay, such panels of reference envs have been generated as molecular clones that are cotransfected with an HIV-1 env-deficient provirus to generate defined stocks of pseudotyped VLPs (Li et al., 2005 (Li et al., , 2006 Seaman et al., 2010) . While the pseudovirion platform is very conducive to the analysis of large panels of envs, it has certain limitations ). Therefore, the Env-IMC-LucR concept incorporated a molecular strategy enabling panels of different env (heterologous ectodomain-encoding region) expressing viruses to be generated, including those from recently described transmitted/founder viruses , since it is this virus that antibody must inhibit to prevent transmission. Several molecular genetic and virologic considerations guided our approach for cloning and expressing env genes of other viral strains, including those from other clades, in the pNL-LucR. T2A backbone. First, the HIV-1 env orf overlaps with vpu and the second exons of both tat and rev. Second, Env incorporation into virions during assembly is facilitated by interaction of amino acids in the C-terminus of Env with those in the N-terminus of p55 Gag (Freed and Martin, 1995) . Since insertion of the entire heterologous env gene into the pNL-LucR. T2A backbone would create genetic chimerisms with tat, rev and vpu, and heterologous protein-protein (MA-Env) interaction, our strategy comprised only the part of the heterologous Env that is exposed on the surface of the virus (the ectodomain) while maintaining the NL4-3 Env cytoplasmic tail. However, the mRNA from which Env is translated forms a complex secondary structural motif (the Rev responsive element, RRE) that mediates the export of unspliced and singly spliced viral RNA from the nucleus via interaction with Rev (Daly et al., 1989) , and thus, our molecular strategy of expressing only the ectodomain of the heterologous env does create a heterologous Rev-RRE interaction (but avoids a chimeric Rev protein). Additional rationale supporting the ectodomain approach was based on observations that neutralization phenotypes of naturally occurring interclade viral recombinants, with recombination points within the env membrane-spanning domain (MSD), were predictable based on the clade/strain of the Env ectodomain (Binley et al., 2004) ; and genetic recombination within the MSD, which is highly conserved, is one of few functionally preferred env recombinant points that naturally occur in vivo (Simon-Loriere et al., 2009) . A panel comprising 27 different clade B envs (ectodomain) has been constructed in the pNL-LucR.T2A backbone to date ), all of which are infectious in PBMC. Panels comprising clade C and A/E envs are currently being constructed and characterized (with 5 and 11 envs, respectively).
Recombinant HIV-1 genomes engineered to express luciferase have been previously described (Chen et al., 1994; Connor et al., 1995; Garcia-Perez et al., 2007; Mariani et al., 2000; Pohlmann et al., 2001; Tokunaga et al., 2001) . However, many of these approaches delete either all or part of the viral env or nef genes in order to insert the luciferase gene. While some of these recombinants may produce infectious virus that report via expression of luciferase from integrated proviral DNA, recombinant virus configurations comprising gene deletions can have deleterious consequences on important virologic function and limit utility of the reporter viruses. Since our goal was to create a luciferase reporter virus that resembled wildtype virus as closely as possible, the Env-IMC-LucR viruses were designed to be replication competent and express all viral genes. Our strategy for retaining efficient expression of nef was to position LucR and nef on the same spliced mRNA linked in-frame via T2A (LucR/ T2A/nef). The LucR gene was selected over firefly luciferase to minimize extending the length of the viral genome. Similarly, the T2A sequence is also much shorter than alternative approaches like IRES. This may, at least in part, explain the relative stability of the recombinant Env-IMC-LucR viruses, which to our knowledge is an important feature that distinguishes this construct from those previously reported. One potential limitation of the T2A approach is that the ribosomal skip mechanism of T2A occurs between the penultimate Gly and adjacent Pro, thus the Nef protein does not have an authentic N-terminus. Consequently, it is unlikely that Nef is post translationally modified by myristoylation, which is important for Nef to associate with the cell's cytoplasmic membrane (Kaminchik et al., 1991) and function in the internalization of various cellular membrane proteins including CD4 and MHC-I (reviewed in (Piguet et al., 1999) ). However, work by Bentham et al. suggests that Nterminally mutated, non-myristoylated Nef may partially retain membrane association and low levels of CD4 down regulation (Bentham et al., 2006) . Thus, additional studies of the Env-IMC-LucR viruses will be required to understand how the altered Nterminus affects Nef function. Nevertheless, our results clearly indicate that the Env-IMC-LucR viruses express the Nef protein and replicate in PBMC with kinetics similar to wild-type virus. Furthermore, due to the presence of Nef, the Env-IMC-LucR viruses have proven useful in CTL assays (Freel et al., 2010) , including those in which responses might be directed against Nef epitopes.
In summary, our findings demonstrate a significant advancement toward the establishment of a standardized PBMC-based neutralization assay platform capable of assessing the quality and potency of NAbs elicited by HIV-1 vaccine immunogens in clinical trials. Although the work described here is focused solely on neutralization in PBMC, the approach was designed to allow for virus infection and/or inhibition assays in any desired target cell, including primary monocyte-derived macrophages, or cells comprising mucosal tissue. Results highlighting the utility of this approach in other primary cell types will be reported elsewhere. The advancements described here are being explored to potentially elucidate immunological correlates of protection against HIV-1 infection recently reported for the ALVAC-HIV and AIDSVAX B/E vaccine regimen that was administered in a Thailand community-based population with largely heterosexual risk (Rerks-Ngarm et al., 2009 ). The Env-IMC-LucR-based viruses described here represent new virologic tools that will facilitate the routine application of a standardized PBMC neutralization assay in the assessment of sera from HIV vaccine trials.
Materials and methods
Cells
The TZM-bl cell line (Wei et al., 2002) was obtained from the NIH AIDS Research and Reference Reagent Program (NIH ARRRP), Division of AIDS, NIAID, NIH (catalog no. 8129), contributed by John Kappes and Xiaoyun Wu. 293T cells were obtained from the American Type Culture Collection (ATCC) (CRL-11268). Both cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), penicillin (100 U/mL) and streptomycin (100 U/mL). NOMI cells (Jones et al., 2007) , a Jurkat-derived cell line engineered to constitutively express high levels of CD4 and CCR5, and express EGFP upon infection with HIV (generously provided by Dr. Olaf Kutsch), were maintained in RPMI 1640 growth medium supplemented with penicillin (100 U/mL), streptomycin (100 U/mL) and L-glutamine (2 mM).
Human primary peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient from buffy coats obtained from healthy HIV-1 seronegative donors. Buffy coats were purchased from Research Blood Components (Brighton, MA) or purified PBMC were provided by Tom Denny (Duke University) and the CAVD CTC-VIMC, as funded by the Bill & Melinda Gates Foundation (grant number 38650). PBMC were cultured in RPMI 1640 growth medium supplemented with penicillin (100 U/mL), streptomycin (100 U/mL), L-glutamine (2 mM), interleukin-2 (IL-2) (30 U/mL) (Roche, Indianapolis, IN) and 10% FBS. The cells were stimulated by culturing in growth medium containing phytohemagglutinin (PHA)-P (2-5 μg/mL) (Sigma-Aldrich) for 24 h. The next day, the medium was removed and the cells were placed into culture with RPMI 1640 containing IL-2 (30 U/mL) and used either immediately, or within 4 days.
Antibodies and anti-viral drugs
Antibodies included HIV-1 Nef antiserum (NIH ARRRP, Catalog #2949, contributed by Ronald Swanstrom), monoclonal antibody (MAb) 183-H12-5C to HIV-1 capsid (NIH ARRRP, contributed by Bruce Chesebro and Hardy Chen), MAb IgG1b12 to HIV-1 gp120 (generously provided by Dennis Burton), MAb 2G12 to HIV-1 gp120 (NIH ARRRP, contributed by Hermann Katinger), MAb 2F5 to HIV-1 gp41 (NIH ARRRP, contributed by Hermann Katinger), MAb 4E10 to HIV-1 gp41 MPER (purchased from Polymun GmbH, Vienna, Austria), and HIVIG (Human Immunodeficiency Virus Immune Globulin) (NIH ARRRP, contributed by Luiz Barbosa), purified IgG prepared from pooled plasma of asymptomatic HIV-1 antibody positive donors with CD4 + counts above 400 cells. The MAb to Renilla luciferase, clone 5B11.2, was purchased from Chemicon International (Catalog no. MAB4400). sCD4 was purchased from Progenics Pharmaceuticals, Inc., Tarrytown, New York. Subtype B plasma samples (1648, 1652 and 1686) were obtained by Duke University (D. Montefiori) from Zeptometrix Corporation (Buffalo, NY). Subtype C plasma samples (BB81 and BB87) were purchased from the South African National Blood Services (Johannesburg) and provided by Lynn Morris, National Institute for Communicable Diseases, Johannesburg, South Africa. The clade A pool (E. Africa), clade C Pool (Tanzania), clade C Pool (Ethiopia) and clade B Pool (United States) were provided by Victoria R. Polonis, Walter Reed Army Institute of Research, Rockville, MD (Seaman et al., 2010) . The fusion inhibitor (T20) was obtained from Trimeris, Inc., Durham, North Carolina. The HIV-1 protease inhibitor, Indinavir Sulfate (IDV), was obtained from the NIH ARRRP, Division of AIDS, NIAID.
Proviral plasmid construction
To generate a luciferase-expressing, replication competent HIV-1 proviral DNA (designated pNL-LucR.T2A), the Renilla reniformis luciferase reporter gene (LucR) from the phRL-CMV vector (Promega) (GenBank ID: AF362549), and a T2A peptide coding sequence (Szymczak et al., 2004) were fused in-frame by PCR methods and inserted between the HIV-1 NL4-3 (GenBank ID: M19921) env and nef genes ( Fig. 1 ; see also Supplemental Fig. 1) . A LucR/T2A/nef (partial) cloning cassette was first engineered by PCR for insertion into a specifically constructed shuttle vector (pCB6_NL_env/nef). Briefly, the LucR gene was amplified from the phRL-CMV vector with the sense primer LucForward, 5′-TAAGCTAGCCA-CCATGGCTTCCAAGGT-3′ (NheI restriction site is italicized and the LucR start codon is underlined), and the antisense primer LucR/T2AReverse, 5′-TCTAGATGGGCCAGGATTCTCCTCGACGTCACCGCATGTTAGCA-GACTTCCTCTGCCCTCCTGCTCGTTCTTCAGCACGCG-3′ (XbaI restriction site is italicized and the T2A peptide sequence is underlined). The reverse primer was designed to remove the stop codon from the LucR gene and to fuse the T2A peptide coding sequence in-frame at the 3′ end of the luciferase gene. In addition, a 5′ fragment of the nef gene was amplified from the NL4-3 genome using the sense primer T2A/nefFoward, 5′-AATCCTGGCCCATCTAGAATGGGTGGCAAGTGGTCA-3′ (T2A sequence is underlined, XbaI restriction site is italicized and the nef start codon is bolded and underlined), and the antisense primer nefReverse, 5′-AGGGAAGTAGCCTTGT-3′ (anneals at NL4-3 nt 10142-10157 downstream of the viral XhoI restriction site (NL4-3 nt 8887) in nef). The T2A/ nefForward primer was designed to be partially complementary to the LucR/T2AReverse primer allowing the two purified PCR products to anneal in a third PCR reaction using primers LucForward and nefReverse to generate a "fusion" PCR product. The fusion PCR product was then cloned into the shuttle vector pCB6_NL_env/nef, a vector derived from plasmid pCB6-EnvA (Ochsenbauer-Jambor et al., 2002) and modified to contain a fragment of the HIV-1 NL4-3 genome from BamHI (NL4-3 nt 8465) in env to KpnI (NL4-3 nt 9005) in nef, utilizing the restriction sites NheI (a specifically engineered restriction site between the env stop codon and the nef start codon) and XhoI. The env/LucR/T2A/nef DNA fragment was then subcloned into the parental pNL4-3 genome using native viral sites BamHI (NL4-3 nt 8465) and XhoI (NL4-3 nt 8887). Sequence analysis confirmed all nucleotides were correct. The resulting proviral plasmid was named pNL-LucR.T2A.
A panel of heterologous env ectodomain containing viruses were constructed with functional env sequences from the R5-tropic viruses BaL (GenBank ID: AY426110) and SF162 (GenBank ID: EU123924) and the clade B transmitted envs from patients WITO4160, 700010040, 700010058, 700010077 (referred to as CH040, CH058 and CH077, respectively) and WEAU0575 . The env ectodomains were amplified with sense primers that anneal upstream of the native viral KpnI sites (NL4-3 nt 6343), and antisense primers to insert a silent BstBI site in the membrane-spanning domains (MSD). Utilizing the KpnI and BstBI sites, the env ectodomain fragments were then inserted into the shuttle vector pSP72.mss, designed with the viral EcoRI (NL4-3 nt 5743) to XhoI (NL4-3 nt 8887) fragment from pNL4-3 with the unique silent BstBI site introduced at nt 8301-8306 in the MSD coding region. The heterologous ectodomain-encoding fragments were then transferred into the pNL4-3 backbone utilizing the EcoRI (NL4-3 nt 5743) and BamHI (NL4-3 nt 8465) sites to generate pNL-BaL.ecto, pNL-SF162.ecto, pNL-WEAU.ecto, pNL-WITO.ecto, pNL-CH040.ecto, pNL-CH058.ecto and pNL-CH077.ecto. The same EcoRI to BamHI fragments were inserted into the pNL-LucR.T2A background, generating pNL-LucR. T2A-BaL.ecto, pNL-LucR.T2A-SF162.ecto, pNL-LucR.T2A-WEAU.ecto, pNL-LucR.T2A-WITO.ecto, pNL-LucR.T2A-CH040.ecto, pNL-LucR.T2A-CH058.ecto and pNL-LucR.T2A-CH077.ecto. Sequence analysis confirmed all nucleotides were correct. The NL-LucR-T2A and NL-LucR. T2A.Env.ecto constructs are collectively referred to as Env-IMC-LucR reporter viruses.
Generation of virus stocks and determination of virus infectivity
293T derived virus stocks were generated by proviral DNA transfection using FuGENE 6 according to the manufacturer's protocol (Roche Applied Science). Viral supernatants were harvested 60 h post-transfection, clarified at 1800×g for 10 min, filtered through 0.45 μm pore size filter and frozen at −70°C. The clarified supernatants were analyzed for HIV-1 p24 antigen concentration by enzyme-linked immunosorbent assay (ELISA) (Perkin-Elmer). Virus stocks were also titered on the TZM-bl reporter cell line by enumeration of β-galactosidase (β-gal) stained colonies as described previously (Wei et al., 2002) . The titered virus stocks were further analyzed for infectivity and LucR gene expression in the TZM-bl cell line. Briefly, 96-well plates were seeded at a density of 2×10 4 cells per well one day prior to infection. The virus was diluted to concentrations of 2 ×10 5 , 2×10 4 , 2×10 3 and 2 ×10 2 TZM-bl infectious units (IU) per well (MOI ranging from 10 to 0.01) and added to the cells in the presence of DEAE-Dextran (40 μg/mL) for 4 h at 37°C. After the 4 h incubation period, the virus was removed and fresh medium was added to the cells for an additional incubation of 48 h. The cells were then washed once with PBS containing Ca++ and Mg++, lysed with 100 μL 1× Renilla luciferase assay lysis buffer (Promega catalog no. E2820) and frozen at −70°C. Samples were freeze/thawed 2 times and 20 μL of each cell lysate were analyzed for both firefly (Promega catalog no. E1501) and LucR activity. Samples were analyzed using a Victor 3 Luminometer (Perkin-Elmer) programmed to inject 100 μL of Luciferase Assay Reagent per well with an exposure time of 10 s/well, and reporting relative light units (RLU)/s.
Western blot analysis
Provirally transfected 293T cells were washed with PBS and lysed with Sample Buffer, Laemmli 2× Concentrate (Sigma-Aldrich), 48 h post-transfection. Lysates were heated for 10 min at 95°C and frozen at −20°C until use. Before use, samples were reheated at 95°C for 10 min and the proteins resolved on a denaturing SDS-polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane, blocked with 10% non-fat dried milk in Tris-buffered saline and reacted with the appropriate primary antibodies to Renilla luciferase, HIV-1 Nef or Gag proteins. The membranes were probed with either anti-mouse or anti-rabbit horseradish peroxidase conjugated secondary antibodies and analyzed by enhanced chemiluminescence.
Replication kinetics
2×10 6 PHA-P stimulated PBMC were infected with 5×10 3 TZM-bl IU (MOI of 0.0025) of virus in a 24-well plate for 4 h. The cells were then washed twice with medium, resuspended in 5 mL of RPMI 1640 containing IL-2 (30 U/mL) and transferred to a T25 flask for the duration of the experiment. Supernatants were collected from the cultures on the indicated sample days and stored at −70°C until samples were collectively analyzed by p24 ELISA. Medium removed for sampling was replenished and midway through the experiment half of the supernatant was replaced with fresh growth medium containing IL-2.
Determination of LucR stability
5×10 3 TZM-bl IU of 293T transfection-derived (TD) virus stocks were used to infect 1.5-2×10 6 PHA-P stimulated PBMC (MOI of 0.0025) in a 24-well plate for 4 h. The cells were then washed twice with fresh medium, resuspended, and cultured in 5 mL of RPMI 1640 containing IL-2 (30 U/mL) for 14 days. Supernatants were collected from the cultures over time, clarified by centrifugation and frozen at −70°C. The amount of supernatant collected on each sample day was replaced with fresh medium. Additionally, the cultures were fed with fresh uninfected cells on day 10 (NL-LucR.T2A-BaL.ecto) or day 6 (NL-LucR.T2A-SF162.ecto). The collected supernatants from days 6, 9 and 14, as well as the cryopreserved transfection-derived stocks, were then used to infect TZM-bl cells for the analysis of both cell-encoded firefly and virallyencoded LucR. Briefly, TZM-bl cells were plated one day prior to infection at 1 × 10 4 cells per well in a 96-well plate. The next day, 5, 1, or 0.2 μL of cell-free PBMC supernatant from the determined time points were added to each well, in triplicate, in the presence of DEAE-Dextran (40 μg/mL) for 4 h. Transfection-derived virus stocks were analyzed in parallel to the PBMC supernatants to determine a baseline stability ratio of Renilla to firefly luciferase. After the 4 h incubation, the media were replaced with fresh media and the samples incubated for 18 h. After the incubation period, the reverse transcriptase inhibitor NVP (5 μM) was added to the cultures to ensure a strictly single-round infection assay. The cells were cultured for an additional 18 h, then lysed with 1× Renilla luciferase lysis buffer and analyzed for both Renilla and firefly luciferase activity. Firefly luciferase activity served as a measure of overall infectivity. The stability of the LucR gene in the viral genome was assessed based on the ratio of the LucR to firefly luciferase expression at different culture intervals.
Neutralization
Inhibition of HIV-1 infection was analyzed in the TZM-bl cell line, the NOMI reporter T-cell line and PBMC. TZM-bl cells were seeded 1 day prior to infection in 96-well plates at a density of 1 × 10 4 cells/well in complete DMEM media. On the day of infection, 2.5 × 10 3 TZM-bl IU of the appropriate virus were incubated with inhibitors diluted to final concentrations of 25, 5, 1, 0.2, 0.04 and 0.008 μg/mL for 1 h at 37°C. The virus/inhibitor mixture was then transferred to the pre-seeded cells and incubated for 48 h in media containing DEAE-Dextran (40 μg/mL). After the incubation, the supernatant was removed and 100 μL of 1× Renilla luciferase assay lysis buffer was added to each well and the samples analyzed for both Renilla and firefly luciferase as described above. To analyze HIV-1 neutralization in NOMI cells, 3 × 10 4 TZM-bl IU of the appropriate virus were added to each well of a 96-well round bottom plate and incubated for 1 h at 37°C with inhibitors prepared as described above. The virus/inhibitor mixture was then transferred to 2×10 5 NOMI cells in a 96-well round bottom plate and the samples were incubated for 48 h at 37°C. At the end of the incubation, 50 μL of 5× Renilla luciferase assay lysis buffer were added directly to each well. Then, 20 μL of each cell lysate were analyzed for LucR activity as described above. A protocol similar to the one used in the NOMI assay was utilized to analyze HIV-1 neutralization in a two-day PBMC assay. The only difference was the amount of virus (6.25 × 10 4 TZM-bl IU) and the number of cells (1× 10 5 PHA-P stimulated PBMC) per well. To analyze HIV-1 neutralization in PBMC in a four-day assay, inhibitors were first diluted into 96-well plates. MAbs and HIVIG were diluted three-fold, starting from a concentration of 25 μg/mL and 2500 μg/mL, respectively. Plasma samples were initially diluted 1:20, followed by seven 3-fold serial dilutions. Next, each virus was added at a concentration that yielded relative light units (RLU) of at least 10 times above background and showed low exponential phase infection after 4 days, and the virus/inhibitor mixture was incubated for 1 h at 37°C. Then, 2-5×10 6 PBMC were added to each well and the cultures were incubated for 4 days. At the end of the incubation, 75 μL of cell suspension were transferred to a white solid plate and 30 μL of diluted VivaRen Renilla luciferase substrate (Promega catalog no. E6495) was added to each well (diluted 10 μL of Renilla Luciferase substrate into 3.5 mL of RPMI (without FBS) for each plate). The plates were read after 4 min by using an exposure of 0.5 s/well (Victor 3 Luminometer, Perkin-Elmer). Percent neutralization was calculated by subtracting the averaged cell control values (cells only) from the averaged sample wells (cells + inhibitor + virus) and dividing this number by the difference in the averaged positive control values (cells + virus) and the averaged cell control values, subtracting this number from 1 and multiplying by 100. Neutralizing titers of patient plasma are expressed as the reciprocal of the plasma dilution required to reduce RLU by 50%.
Supplementary materials related to this article can be found online at doi:10.1016/j.virol.2010.08.028.
